Does Rallies show Form 4 insider transactions for AIM?

Yes. Rallies tracks AIM insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is AIM research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AIM. It does not provide personalized investment advice.

AIM (AIM ImmunoTech Inc.) Stock Analysis - Insider Trades

AIM ImmunoTech Inc. (AIM) is a publicly traded Healthcare sector company. As of May 21, 2026, AIM trades at $0.26 with a market cap of $6.36M and a P/E ratio of -0.05. AIM moved -38.69% today. Year to date, AIM is -80.10%; over the trailing twelve months it is +102.64%. Its 52-week range spans $0.06 to $20.33. Analyst consensus is buy with an average price target of $10.00. Rallies surfaces AIM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading AIM stock inside the company?

Recent AIM insider activity includes Equels Thomas K bought 107, Equels Thomas K bought 103, MITCHELL WILLIAM M bought 196.85K, Equels Thomas K bought 1.97M, and KELLNER TED D bought 1.97M. Rallies tracks insider transaction dates, shares, prices, and estimated values.

AIM Key Metrics

Key financial metrics for AIM
Metric	Value
Price	$0.26
Market Cap	$6.36M
P/E Ratio	-0.05
EPS	$-8.62
Dividend Yield	0.00%
52-Week High	$20.33
52-Week Low	$0.06
Volume	11.72M
Avg Volume	0
Revenue (TTM)	$88.00K
Net Income	$-13.96M
Gross Margin	0.00%

Recent AIM Insider Trades

Equels Thomas K bought 107 (~$823.579) on Jun 13, 2025.
Equels Thomas K bought 103 (~$896.1) on Jun 12, 2025.
MITCHELL WILLIAM M bought 196.85K (~$5.00K) on Apr 11, 2025.
Equels Thomas K bought 1.97M (~$50.00K) on Apr 11, 2025.
KELLNER TED D bought 1.97M (~$50.00K) on Apr 11, 2025.

Latest AIM News

AIM ImmunoTech Raises $2.4 Million via 7.52 M Shares and 15 M Series I Warrants — May 20, 2026
AIM ImmunoTech Shows 50% ORR, 21% Complete Responses in Phase 2 Ovarian Cancer Trial — May 7, 2026
AIM ImmunoTech Plans Phase 3 Pancreatic Cancer Trial After Over 100-Patient Phase 2 Success — Apr 16, 2026
AIM ImmunoTech Flags Going Concern, Cites Positive Phase 2 Pancreatic Cancer Data — Apr 13, 2026
Directa Plus warns of administration risk without £2.5m funding; Greatland grows Telfer to 8Moz; 88 Energy targets 64m barrels — Mar 30, 2026

AIM Analyst Consensus

1 analysts cover AIM: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $10.00.

Common questions about AIM

Who is trading AIM stock inside the company?: Recent AIM insider activity includes Equels Thomas K bought 107, Equels Thomas K bought 103, MITCHELL WILLIAM M bought 196.85K, Equels Thomas K bought 1.97M, and KELLNER TED D bought 1.97M. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for AIM?: Yes. Rallies tracks AIM insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is AIM research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AIM. It does not provide personalized investment advice.